Risperidone long-acting injection (LAI) for schizophrenia
This study was terminated in Australia, in Canada, in the United Kingdom, .... It is testing Risperidone long-acting injection (LAI) for schizophrenia.
SchizophreniaDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Risperidone Long-Acting Injection Versus Oral Antipsychotics may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Risperidone Long-Acting Injection Versus Oral Antipsychotics, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Australia, in Canada, and in Ireland.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateJanuary 2006
Recruitment status
Terminated
Enrollment listed in the registry
167
Sponsor
Janssen-Ortho Inc., Canada
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Australia, Canada, United Kingdom, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00256997
Official title
Pragmatic Randomized Trial of Risperdal Consta Versus Oral Atypical Antipsychotics in Poorly Adherent Subjects With Schizophrenia in a Routine Care Setting
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Australia · 5 sites
Dandenong
Dandenong
Site status: Not listed — confirm with the team
Frankston
Frankston
Site status: Not listed — confirm with the team
Mount Claremont
Mount Claremont
Site status: Not listed — confirm with the team
Newcastle
Newcastle
Site status: Not listed — confirm with the team
Southport
Southport
Site status: Not listed — confirm with the team
Canada · 15 sites
Calgary
Calgary, Alberta
Site status: Not listed — confirm with the team
Bathurst
Bathurst, New Brunswick
Site status: Not listed — confirm with the team
Kentville
Kentville, Nova Scotia
Site status: Not listed — confirm with the team
Sydney
Sydney, Nova Scotia
Site status: Not listed — confirm with the team
Greater Sudbury
Greater Sudbury, Ontario
Site status: Not listed — confirm with the team
Kingston
Kingston, Ontario
Site status: Not listed — confirm with the team
Mississauga
Mississauga, Ontario
Site status: Not listed — confirm with the team
Beauport
Beauport, Quebec
Site status: Not listed — confirm with the team
Montreal
Montreal, Quebec
Site status: Not listed — confirm with the team
Québec
Québec, Quebec
Site status: Not listed — confirm with the team
Saint-Georges
Saint-Georges, Quebec
Site status: Not listed — confirm with the team
Battleford
Battleford, Saskatchewan
Site status: Not listed — confirm with the team
Prince Albert
Prince Albert, Saskatchewan
Site status: Not listed — confirm with the team
Montreal
Montreal
Site status: Not listed — confirm with the team
Saint John
Saint John
Site status: Not listed — confirm with the team
Ireland · 3 sites
Co.Mayo
Co.Mayo
Site status: Not listed — confirm with the team
Dublin
Dublin
Site status: Not listed — confirm with the team
Mullingar
Mullingar
Site status: Not listed — confirm with the team
United Kingdom · 21 sites
Birmingham
Birmingham
Site status: Not listed — confirm with the team
Boston
Boston
Site status: Not listed — confirm with the team
Bristol
Bristol
Site status: Not listed — confirm with the team
Burnley
Burnley
Site status: Not listed — confirm with the team
Darwen
Darwen
Site status: Not listed — confirm with the team
Devon
Devon
Site status: Not listed — confirm with the team
Grantham
Grantham
Site status: Not listed — confirm with the team
Leicester
Leicester
Site status: Not listed — confirm with the team
Lincoln
Lincoln
Site status: Not listed — confirm with the team
London
London
Site status: Not listed — confirm with the team
Morpeth
Morpeth
Site status: Not listed — confirm with the team
Newcastle upon Tyne
Newcastle upon Tyne
Site status: Not listed — confirm with the team
Northampton
Northampton
Site status: Not listed — confirm with the team
Nottingham
Nottingham
Site status: Not listed — confirm with the team
Preston
Preston
Site status: Not listed — confirm with the team
Stamford
Stamford
Site status: Not listed — confirm with the team
Stockton-Upon-Tees
Stockton-Upon-Tees
Site status: Not listed — confirm with the team
Swansea
Swansea
Site status: Not listed — confirm with the team
Teignmouth
Teignmouth
Site status: Not listed — confirm with the team
Wallsend
Wallsend
Site status: Not listed — confirm with the team
Weston-super-Mare
Weston-super-Mare
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00256997. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Risperidone long-acting injection (LAI), Oral atypical Antipsychotic. Phase 4 studies usually happen after treatment approval, to monitor real-world use.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Janssen-Ortho Inc., Canada, which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
